Koers Sienna Biopharmaceuticals, Inc.
Aandelen
SNNAQ
US82622H1086
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,000001 USD | -.--% | -.--% | -.--% |
Omzet 2017 | - | Omzet 2018 | - | Marktkapitalisatie | 48,12 mln. 44,88 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2017 | -50 mln. -46,63 mln. | Nettowinst (verlies) 2018 | -73 mln. -68,08 mln. | EV/omzet 2017 | - |
Nettoliquiditeiten 2017 | 74,47 mln. 69,45 mln. | Nettoliquiditeiten 2018 | 18,4 mln. 17,16 mln. | EV/omzet 2018 | - |
K/w-verhouding 2017 |
-3,5
x | K/w-verhouding 2018 |
-0,65
x | Werknemers | 13 |
Dividendrendement 2017 * |
-
| Dividendrendement 2018 |
-
| Vrij verhandelbaar | 99,54% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 59 | 27-06-10 | |
Majed Kheir
COO | Chief Operating Officer | 46 | 01-01-16 |
Silvio Traversa
CTO | Chief Tech/Sci/R&D Officer | 54 | 01-12-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Dennis Fenton
BRD | Director/Board Member | 72 | 01-10-16 |
Founder | 59 | 27-06-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-.--% | 22 | |
-2,63% | 102 mld. | |
+1,62% | 96,29 mld. | |
+2,36% | 22,18 mld. | |
-16,67% | 21,2 mld. | |
-9,16% | 18,31 mld. | |
-38,74% | 17,38 mld. | |
-13,21% | 16,36 mld. | |
+5,41% | 13,97 mld. | |
+33,57% | 12,17 mld. |